Alana MBA - EFFECTOR Therapeutics Chief Officer
Insider
Alana MBA is Chief Officer of EFFECTOR Therapeutics
| Age | 61 |
| Phone | 858 925 8215 |
| Web | https://effector.com |
EFFECTOR Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.8333) % which means that it has lost $0.8333 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (9.4656) %, meaning that it generated substantial loss on money invested by shareholders. EFFECTOR Therapeutics' management efficiency ratios could be used to measure how well EFFECTOR Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Heather Prichard | Humacyte | 47 | |
| Kiernan MD | Humacyte | N/A | |
| Suzanne Messere | NRx Pharmaceuticals | N/A | |
| Marc Cantillon | Reviva Pharmaceuticals Holdings | 66 | |
| Laxminarayan Bhat | Reviva Pharmaceuticals Holdings | 60 | |
| Seth Voorhees | NRx Pharmaceuticals | 63 | |
| Robert MIM | NRx Pharmaceuticals | 58 | |
| Michael Kunz | NRx Pharmaceuticals | 59 | |
| B Scheessele | Humacyte | N/A | |
| Dennis McBride | NRx Pharmaceuticals | N/A | |
| Narayan Prabhu | Reviva Pharmaceuticals Holdings | 53 | |
| Philip Lavin | NRx Pharmaceuticals | 78 | |
| MS MS | Humacyte | 66 | |
| Dale Sander | Humacyte | 65 | |
| Molly Cogan | NRx Pharmaceuticals | N/A | |
| Prof Javitt | NRx Pharmaceuticals | N/A | |
| MPH MD | NRx Pharmaceuticals | 68 | |
Management Performance
| Return On Equity | -9.47 | |||
| Return On Asset | -0.83 |
EFFECTOR Therapeutics Leadership Team
Elected by the shareholders, the EFFECTOR Therapeutics' board of directors comprises two types of representatives: EFFECTOR Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EFFECTOR. The board's role is to monitor EFFECTOR Therapeutics' management team and ensure that shareholders' interests are well served. EFFECTOR Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EFFECTOR Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Siegfried Reich, CoFounder Advisor | ||
| Mayank MD, Chief Officer | ||
| Michael MBA, Chief Officer | ||
| Alana MBA, Chief Officer | ||
| Premal MD, Chief Officer | ||
| Davide Ruggero, CoFounder Board | ||
| Douglas MD, Chief Officer | ||
| Stephen Worland, President CEO | ||
| Kevan Shokat, CoFounder Board |
EFFECTOR Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is EFFECTOR Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -9.47 | |||
| Return On Asset | -0.83 | |||
| Number Of Shares Shorted | 18.44 K | |||
| EBITDA | (33.73 M) | |||
| Net Income | (35.81 M) | |||
| Total Debt | 19.45 M | |||
| Book Value Per Share | 0.21 X | |||
| Cash Flow From Operations | (29.55 M) | |||
| Earnings Per Share | (0.91) X | |||
| Number Of Employees | 14 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Consideration for investing in EFFECTOR Pink Sheet
If you are still planning to invest in EFFECTOR Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EFFECTOR Therapeutics' history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |